X-CLX-Shades: |
Deliver |
X-CLX-Response: |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 |
Date: |
Sat, 8 Feb 2025 15:16:13 +0100 |
Reply-To: |
|
Approved-By: |
|
Message-ID: |
|
MIME-Version: |
1.0 |
Subject: |
|
Emisor: |
|
Received: |
by LISTSERV.REDIRIS.ES (LISTSERV-TCP/IP release 17.0) with spool id
1222635 for [log in para visualizar]; Sat, 8 Feb 2025 16:20:26
+0100
from mx07-006a4e02.pphosted.com (mx07-006a4e02.pphosted.com
[143.55.146.78]) by listserv.backend.rediris.es (Postfix) with ESMTP
id 2986B20EFB1 for < [log in para visualizar]>; Sat, 8 Feb
2025 15:16:15 +0100 (CET)
from pps.filterd (m0316687.ppops.net [127.0.0.1]) by
m0316687.ppops.net (8.18.1.2/8.18.1.2) with ESMTP id 518DoncN027838
for < [log in para visualizar]>; Sat, 8 Feb 2025 15:16:14 +0100
from satellite02.sim.rediris.es (satellite02.sim.rediris.es
[130.206.24.61]) by m0316687.ppops.net (PPS) with ESMTPS id
44p0st4shy-1 (version=TLSv1.2 cipher=ECDHE-RSA-AES256-GCM-SHA384
bits=256 verify=NOT) for < [log in para visualizar]>; Sat, 08
Feb 2025 15:16:14 +0100 (CET)
from satellite02.sim.rediris.es (localhost.localdomain [127.0.0.1])
by satellite02.sim.rediris.es (Postfix) with ESMTPS id E2B30C00E8 for
< [log in para visualizar]>; Sat, 8 Feb 2025 15:16:13 +0100
(CET)
from localhost (localhost.localdomain [127.0.0.1]) by
satellite02.sim.rediris.es (Postfix) with ESMTP id DD44EC0172 for
< [log in para visualizar]>; Sat, 8 Feb 2025 15:16:13 +0100
(CET)
from satellite02.sim.rediris.es ([127.0.0.1]) by localhost
(satellite02.sim.rediris.es [127.0.0.1]) (amavis,
port 10026) with ESMTP id KusZp5H82DEV for
< [log in para visualizar]>; Sat, 8 Feb 2025 15:16:13 +0100
(CET)
from web-node01.backend.rediris.es (web-node01.backend.rediris.es
[130.206.25.31]) by satellite02.sim.rediris.es (Postfix) with ESMTP
id CF911C00E8 for < [log in para visualizar]>; Sat, 8 Feb 2025
15:16:13 +0100 (CET)
by web-node01.backend.rediris.es (Postfix,
from userid 48) id 8454314EC9; Sat, 8 Feb 2025 15:16:13 +0100 (CET) |
Content-Type: |
text/plain; charset=UTF-8; |
X-Amavis-Modified: |
Mail body modified (using disclaimer) -
satellite02.sim.rediris.es |
Delivered-To: |
|
X-Proofpoint-ORIG-GUID: |
USlpqMMt3CTJqfzqIhzBj4V7aDgESL-M |
Sender: |
|
X-Proofpoint-Spam-Details: |
rule=politica_listserv_notspam
policy=politica_listserv score=0 malwarescore=0
bulkscore=0 adultscore=0 spamscore=0 mlxscore=0
phishscore=0 suspectscore=0 clxscore=1000
impostorscore=0 priorityscore=1000
lowpriorityscore=0 mlxlogscore=999
classifier=customer_allow adjust=0 reason=mlx
scancount=1 engine=8.19.0-2501170000
definitions=main-2502080119 domainage_hfrom=1635 |
X-Proofpoint-Virus-Version: |
vendor=baseguard
engine=ICAP:2.0.293,Aquarius:18.0.1057,Hydra:6.0.680,FMLib:17.12.68.34
definitions=2025-02-08_06,2025-02-07_03,2024-11-22_01 |
X-Proofpoint-GUID: |
USlpqMMt3CTJqfzqIhzBj4V7aDgESL-M |
Parts/Attachments: |
|
|
===
Para darse de ALTA/BAJA del Boletin OFER-TRABEC utilice el siguiente enlace o pongase en contacto con [log in para visualizar]
https://listserv.rediris.es/cgi-bin/wa?SUBED1=OFER-TRABEC&A=1
===
SEGURIDAD: Los enlaces contenidos en este mensaje son seguros y protegidos con reescritura de URL_DEFENSE de Proofpoint
===
---Procedencia:
Institución:Institut de Recerca Biomèdica de Lleida (IRBLleida)
Contacto correo-e:[log in para visualizar]
---
The Molecular Oncology group (http://bit.ly/molonco) at Institut de Recerca Biomèdica de Lleida (IRBLleida) is looking for a highly motivated candidate to apply for a tenure track researcher position funded by the ‘Miguel Servet’ Program of the Spanish Government through the Instituto de Salud Carlos III Universities (https://bit.ly/41heTEd).
The group strategic lines in the oncology field are:
1) Investigation of the molecular mechanisms underlying the initiation and progression of gastrointestinal tumors (colorectal and gastric), with the ultimate goal of improving the diagnosis and treatment of patients.
2) Personalization of the chemotherapeutic treatment in patients with colorectal cancer. Our laboratory has been interested for long time in identifying new molecular biomarkers capable of predicting the response of patients with colorectal cancer to the treatment with small molecule chemotherapeutic agents.
For this position it is:
Required:
- Hold a PhD degree in biological or biomedical sciences obtained between January 2013 and December 2020 (with the exceptions listed in the call),
- Strong publication record as first/last author in indexed international journals in the first decile/quartile,
- Have professional experience in top national/international research institutions,
- Write a research project in the field of gastrointestinal cancer research.
Valued:
- Participation in research projects and mobility,
- Direction of graduate, master's and/or undergraduate students,
- Organizational, proactive and self-motivated attitude,
- Communication skills.
Offered:
- Full-time 5 years contract (3+2),
- Remuneration: 40.500€/year (gross annual salary),
- 40.000€ bench-fees for the execution of research activity,
- Institutional tenure track programme. IRBLleida has established a tenure track programme to stabilize Miguel Servet researchers that upon their 5-year contract are positively evaluated by the Instituto de Salud Carlos III. After obtaining the tenure track position at our institute, the candidate will be evaluated every five years by the Scientific Council of Institut Català de la Salut. The result of the evaluation will determine whether the researcher is economically promoted or maintained in the same salary range. Eventually, if the result of the evaluation is not positive, specific actions will be put in place to assist the researcher to improve his/her scientific track in a given period of time and prevent the interruption of the contract,
- Skillful and social colleagues, a highly stimulating and dynamic scientific environment, state-of-the-art infrastructures, challenging tasks, wide range of responsibilities and unique professional career development opportunities.
Application Procedure:
The number of applications for Miguel Servet positions is restricted by Instituto de Salud Carlos III. Each recognized research institute can only apply for 5 positions. Accordingly, an internal prioritization selection process will take place at IRBLleida (see bellow).
All applications must be addressed by email to [log in para visualizar] and include:
- A complete CV,
- A motivation letter,
- Contact details for reference.
Please, indicate MS2025-RI in the subject.
The submission deadline will end on February 14th 2025 at 12h.
Selection process:
- The group will select a candidate based on the CV, motivation letter, experience and personal interview.
- The selected candidate will apply to IRBLleida internal prioritization phase by addressing a letter of interest to the Institute’s Grants Office before February 17th 2025 (15:00h), and the application documents that will be provided, before February 21st 2025 (15:00h).
- The internal prioritization process will be as follows:
1) Assessment of the curricular merits of the candidates (eliminatory phase).
2) Personal interview (interest in joining IRBLleida and ability to generate collaborations and synergies with the Institute's research groups).
A full description of the internal priorization process is available in the following link: https://bit.ly/3CGKqWt.
- The selected candidate by IRBLleida will apply for the position to Instituto de Salud Carlos III before March 5th 2025.
----------------
Información complementaria de la oferta:
The Institute:
IRBLleida acts as a cluster of all biomedical research carried out in Lleida and incorporates to two stakeholders that conduct health research and implement innovation policies:
. The University of Lleida (UdL) includes researchers from the Faculties of Medicine, Nursing and Physiotherapy.
· The Department of Health, includes researchers from Arnau de Vilanova University Hospital (HUAV), Santa María University Hospital (HUSM), Catalan Health Institute (ICS) and Lleida Primary Care and Community.
IRBLleida is a CERCA center, the biocluster supported and supervised by the Autonomous Government of Catalonia, and it is also accredited as a Centre of Excellence by Carlos III Health Institute (funded by Spanish Government).
We offer and promote a diverse and inclusive environment and welcome applicants regardless gender, nationality, ethnicity or religion. IRBLleida is awarded with the 'HR Excellence in Research' from the European Commission. This recognition reflects the commitment of IRBLleida recruitment and appraisal procedures in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers.
|